Laser capture microdissection: A tool for the molecular characterization of histologic subtypes of lung adenocarcinoma

International Journal of Molecular Medicine

Volumn 24, Issue 4, 2009, Pages 473-479

  Donati, Valentina ^a   Lupi, Cristiana ^b   Ali, Greta ^b   Corsi, Valentina ^b   Viti, Andrea ^b   Lucchi, Marco ^b   Mussi, Alfredo ^b   Fotanini, Gabriella ^b  

^a AUO Pisa   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

EGFR mutations; Laser capture microdissection; Lung adenocarcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KERATIN; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; EXON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL CARCINOMA; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; LASERS; LUNG NEOPLASMS; MALE; MICRODISSECTION; MIDDLE AGED;

EID: 70350755350     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000255     Document Type: Article

References (20)

1. Travis WD, Travis LB and Devesa SS: Lung cancer. Cancer 75: 191-202, 1995.
2. Pugh TJ, Bebb G, Barclay L, et al: Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer 7: 128, 2007.
3. Rosell R, Ichinose Y, Taron M, et al: Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50: 25-33, 2005.
4. Immervoll H, Hoem D, Kugarajh K, et al: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 448: 788-796, 2006.
5. Tzeng CW, Frolov A, Frolova N, et al: Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141: 464-469, 2007.
6. Yang D, Schneider S, Azuma M, et al: Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer 6: 305-311, 2006.
7. Nagahara H, Mimori K, Ohta M, et al: Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11: 1368-1371, 2005.
8. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
9. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
10. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
11. Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262, 2006.
12. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W and Varmus HE: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510, 2006.
13. Ji H, Li D, Chen L, et al: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495, 2006.
14. Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26: 1472-1478, 2008.
15. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158, 2003.
16. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) (corrected). J Clin Oncol 21: 2237-2246, 2003.
17. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109, 2004.
18. Motoi N, Szoke J, Riely GJ, et al: Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32: 810-827, 2008.
19. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
20. Read WL, Page NC, Tierney RM, Piccirillo JF and Govindan R: The epidemiology of bronchioloalveolar carcinoma over the past two decades. Analysis of the SEER database. Lung Cancer 45: 137-142, 2004.